Summary & Overview
HCPCS J2670: Tolazoline HCl Injection, up to 25 mg
HCPCS Level II code J2670 represents the administration of tolazoline hydrochloride injectable, up to 25 mg. As an HCPCS Level II drug code, it identifies a specific parenteral medication used in clinical settings where injectable vasodilatory or pharmacologic interventions are required. Nationally, accurate coding for injectable medications affects claim processing, reimbursement consistency, and inventory tracking across hospital, ambulatory surgery, and physician office settings.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise presentation of what the code denotes clinically and operationally, and an overview of typical sites of service. The publication provides benchmarks and policy-relevant context where available, clarifies payer coverage scope, and outlines coding nuances for billing teams and revenue cycle staff.
The content covers: the clinical purpose and administration context for J2670; common payer coverage considerations and how major public and private payers treat injectable HCPCS drug codes; operational implications for claims submission and site-of-service designation; and where to find related coding guidance. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J2670 describes an injection of tolazoline hydrochloride, up to 25 mg. The service is a pharmacologic injectable therapy typically administered parenterally. Typical sites of service include hospital inpatient or outpatient settings, ambulatory surgical centers, and physician offices where injectable medications are given.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A neonate in the neonatal intensive care unit (NICU) with persistent pulmonary hypertension of the newborn (PPHN) or severe neonatal cyanotic episodes receives intra-arterial or intravenous vasodilator therapy. Tolazoline hydrochloride (J2670) is administered as an injection, typically by a neonatologist, pediatric intensivist, or neonatal pharmacist preparing a weight-based vial dose (up to 25 mg). The clinical workflow includes patient assessment (vital signs, oxygenation, echocardiography to evaluate pulmonary hypertension), informed consent from the parent or guardian, preparation of the medication under sterile technique, administration via existing intravenous or intra-arterial access, continuous monitoring for hypotension and tachycardia, and documentation of dose, route, time, response, and any adverse effects in the medical record. The typical site of service is the neonatal intensive care unit or pediatric critical care unit; administration can also occur in a pediatric emergency department for acute cyanotic events. Billing uses the HCPCS Level II code J2670 to report the tolazoline injection up to 25 mg, with appropriate visit or procedure codes captured separately for monitoring, ventilation, or invasive support as clinically applicable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard reporting |